Prevention of superantigen-induced down-regulation of T-cell mediated cytotoxic activity by IL-2 in vivo

Immunology

Volumn 90, Issue 2, 1997, Pages 183-188

  Belfrage, H ^a   Dohlsten, M ^a,b   Hedlund, G ^a,b   Kalland, T ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b Pharmacia & Upjohn AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; STAPHYLOCOCCUS ENTEROTOXIN A; SUPERANTIGEN; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; FEMALE; IMMUNOREGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0031030721     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.1997.00030.x     Document Type: Article

References (32)

1. MARRACK P. & KAPPLER J. (1990) The staphylococcal enterotoxins and their relatives. Science 248, 705.
2. + cells to bacterial superantigens. Eur J Immunol 22, 1935.
3. DOHLSTEN M., BJÖRKLUND M., SUNDSTEDT A., HEDLUND G., SANSOM D. & KALLAND T. (1993) Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor Vβ3 transgenic mice. Immunology 79, 520.
4. HEDLUND G., DOHLSTEN M., PETERSSON C. & KALLAND T. (1993) Superantigen-based tumor therapy: in vivo activation of cytotoxic T cells. Cancer Immunol Immunother 36, 89.
5. KALLAND T., HEDLUND G., DOHLSTEN M. & LANDO P.A. (1991) Staphylococcal enterotoxin dependent cell-mediated cytotoxicity. Curr Top Microbiol Immunol 174, 81.
6. DOHLSTEN M., HEDLUND G., ÅKERBLOM E., LANDO P.A. & KALLAND T. (1991) Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents. Proc Natl Acad Sci USA 88, 9287.
7. DOHLSTEN M., ABRAHAMSÉN L., BJÖRK P. et al. (1994) Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell based tumor therapy. Proc Natl Acad Sci USA 91, 8945.
8. + Tcells in mice tolerant to Staphylococcus aureus enterotoxin B. Nature 349, 245.
9. + peripheral T cells responding to staphylococcal enterotoxin B in vivo. Eur J Immunol 21, 1963.
10. + cells in staphylococcal enterotoxin B-primed mice. J Exp Med 172, 1065.
11. + T cells by staphylococcal enterotoxin B. J Exp Med 172, 1091.
12. DOHERTY P.C. (1993) Cell-mediated cytotoxicity. Cell 75, 607.
13. H2-like phenotype. J Exp Med 179, 481.
14. MUELLER D.L., JENKINS M.K. & SCHWARTZ R.H. (1989) Clonal expansion vs. functional clonal inactivation: a costimulatory signailing pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 7, 445.
15. BELFRAGE H., DOHLSTEN M., HEDLUND G. & KALLAND T. (1995) Enhanced and prolonged efficacy of superantigen induced CTL activity by IL-2 in vivo. Cancer Immunol Immunther 41, 87.
16. + mononuclear leukocytes and freshly prepared leukaemia cells. Cell Immunol 129, 426.
17. LAGOO A.S., LAGOO-DEENADAYALAN S., LORENZ A.-M., BYRNE J., BARBER W.H. & HARDY K.J. (1994) IL-2, IL-4, and IFN-γ gene expression vs. secretion in superantigen-activated T cells. Distinct requirement for costimulatory signals through adhesion molecules. J Immunol 152, 1641.
18. HERMAN A., KAPPLER J.W., MARRACK P. & PULLEN A.M. (1991) Superantigens: mechanism of T-cell stimulation and role in immune responses. Ann Res Immunol 9, 745.
19. SUNDSTEDT A., DOHLSTEN M., HEDLUND G. et al. (1994) Superantigens anergize cytokine production but not cytotoxicity in vivo. Immunology 82, 117.
20. GONZALO J.A., MORENO DE ALBORÁN I., ALÉS-MARTINEZ J., MARTINEZ-A C. & KROEMER G. (1992) Expansion and clonal deletion of peripheral T cells induced by bacterial superantigen is independent of the interleukin-2 pathway. Eur J Immunol 22, 1007.
21. MCCORMACK J.E., CALLAHAN J.E., KAPPLER J. & MARRACK P.C. (1993) Profound deletion of mature T cells in vivo by chronic exposure to exogenous superantigen. J Immunol 150, 3785.
22. KEENE J. & FORMAN J. (1982) Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med 155, 768.
23. SCHOLS D., VANDEKERCKHOVE B., JONES D. & RONCAROLO M.-G. (1994) IL-2 reverses human T cell unresponsiveness induced by thymic epithelium in SCID-hu mice. J Immunol 152, 2198.
24. DALLMAN M.J., SHIHO O., PAGE T.H., WOOD K.J. & MORRIS P.J. (1991) Peripheral tolerance to alloantigen results from altered regulation of the interleukin-2 pathway. J Exp Med 173, 79.
25. + T cells induces functional but non-proliferative T cells in vivo. Immunology 83, 333.
26. BEVERLY B., KANG S., LENARDO M. & SCHWARTZ R. (1992) Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int Immunol 4, 661.
27. ESSERY G., FELDMANN M. & LAMP J. (1988) Interleukin-2 can prevent and reverse antigen-induced unresponsiveness in cloned human T lymphocytes. Immunology 64, 413.
28. BOUSSIOTIS V., FREEMAN G., GRAY G., GRIBBEN J. & NADLER L. (1993) B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med 178, 1753.
29. BOUSSIOTIS V.A., BARBER D.L., NAKARAI T. et al. (1994) Prevention of T cell anergy by signalling through the γ- chain of the IL-2 receptor. Science 266, 1039.
30. CHEEVER M.A., THOMPSON J.A., PEACE D.J. & GREENBERG P.D. (1986) Potential uses of interleukin-2 in cancer therapy. Immunobiol 172, 365.
31. SMYTH M.J., ORTALDO J.R., BERE W., YAGITA H., OKUMURA K. & YOUNG H.A. (1990) IL-2 and IL-6 synergize to augment the pore-forming protein gene expression and cytotoxic potential of human peripheral blood T cells. J Immunol 145, 1159.
32. + T cells. J Exp Med 171, 1269.